The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy.
tagAlzheimer's drug embrace slows down as US doctors' reluctance growsThe adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy. sharesave
